NSTC Developing New Plans to Reduce Foreign Influence on U.S. Research
Co-chair of the National Science and Technology Council (NSTC) Kelvin Droegemeier, PhD, is developing new requirements for what information researchers must disclose to receive...
Opioid Manufacturers Reach Settlements in State Lawsuits
Large drug manufacturer Purdue Pharma has agreed to pay $10 billion to settle more than 2,600 lawsuits filed by states, cities, counties, individuals, and...
Heparin-Induced Thrombocytopenia Does Not Appear to Protect Against Major Bleeding
Patients with heparin-induced thrombocytopenia (HIT), a prothrombotic complication of heparin exposure, are believed to be protected against anticoagulant-associated bleeding, but results from a retrospective analysis...
Older Patients with iTTP Have Delayed Diagnosis and Higher Mortality Than Younger Counterparts
Older patients diagnosed with immune thrombotic thrombocytopenic purpura (iTTP) have worse short- and long-term mortality compared with younger patients and the general population, according...
Eltrombopag Induces Complete Platelet Responses in Patients with Lymphoproliferative Disorders and Treatment-Resistant ITP
Results from a small phase II trial suggest that treatment with eltrombopag was associated with sustained platelet responses and complete responses (CRs) in patients...
Study Identifies Familial Risk Patterns of Several Hematologic Malignancies
People who have a first-degree relative diagnosed with a hematologic malignancy have a higher risk of developing a blood cancer, according to an analysis...
With PET-Guided Treatment, Can Radiation Be Eliminated in Early-Stage HL?
Combined modality treatment (CMT) consisting of chemotherapy and small-field radiotherapy has long been considered the standard of care for patients with early-stage, favorable Hodgkin...
Remembering Thomas P. Stossel, CPRIT Awards $136 Million in 71 New Grants, and more
Remembering Thomas P. Stossel (1941 – 2019)
Thomas P. Stossel, MD, former president of the American Society of Hematology (ASH), passed away unexpectedly on September...
FDA Places Trials of MCL-1 Inhibitor on Clinical Hold
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on a phase I, dose-escalation study of AMG 397, an oral, small...
ASH Announces Three New Executive Committee Members, Free Childcare at the 2019 ASH Annual...
Congratulations to ASH’s Three New Executive Committee Members
The American Society of Hematology (ASH) has announced the election of three new members to its Executive...
Current Issue
December 2019, Volume 5, Issue 15
This issue examines the hidden costs of participating in clinical trials, explores the pediatric hematology/oncology workforce, and more.
